Foundation Resource Management Inc. Has $6.21 Million Stake in AbbVie Inc. (NYSE:ABBV)
Foundation Resource Management Inc. Has $6.21 Million Stake in AbbVie Inc. (NYSE:ABBV)
Foundation Resource Management Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,557 shares of the company's stock after selling 80 shares during the period. Foundation Resource Management Inc.'s holdings in AbbVie were worth $6,212,000 at the end of the most recent reporting period.
基金資源管理公司最近提交給美國證券交易委員會的文件顯示，該公司在第二季度將其持有的艾伯維公司股票的倉位下調了0.2%。該基金在此期間出售了80股後，持有該公司40,557股股票。在最近一次報告期結束時，基金會資源管理公司在AbbVie持有的股份價值6,211,000美元。
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Intelligent Financial Strategies bought a new position in AbbVie in the 4th quarter valued at approximately $27,000. Psagot Value Holdings Ltd. Israel raised its holdings in AbbVie by 311.3% in the 4th quarter. Psagot Value Holdings Ltd. Israel now owns 4,360 shares of the company's stock valued at $28,000 after buying an additional 3,300 shares during the last quarter. GoalVest Advisory LLC bought a new position in AbbVie in the 1st quarter valued at approximately $33,000. Joseph P. Lucia & Associates LLC bought a new position in AbbVie in the 1st quarter valued at approximately $34,000. Finally, Landmark Wealth Management LLC bought a new position in AbbVie in the 1st quarter valued at approximately $42,000. Institutional investors and hedge funds own 68.25% of the company's stock.
其他一些機構投資者和對衝基金也買賣了該公司的股票。智能財務策略公司在第四季度購買了AbbVie的一個新頭寸，價值約為27,000美元。以色列Psagot Value控股有限公司在第四季度將其在AbbVie的持股增加了311.3%。以色列Psagot Value Holdings Ltd.在上個季度又購買了3,300股Psagot Value Holdings Ltd.股票後，現在持有該公司4,360股股票，價值28,000美元。GoalVest Consulting LLC在第一季度購買了AbbVie的一個新頭寸，價值約為3.3萬美元。Joseph P.Lucia&Associates LLC在第一季度購買了AbbVie的一個新頭寸，價值約3.4萬美元。最後，Landmark Wealth Management LLC在第一季度購買了AbbVie的一個新頭寸，價值約為42,000美元。機構投資者和對衝基金持有該公司68.25%的股票。
AbbVie Stock Performance
艾伯維股票表現
Shares of ABBV stock opened at $143.06 on Friday. The company has a market cap of $252.94 billion, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 4.02 and a beta of 0.72. AbbVie Inc. has a 52 week low of $106.44 and a 52 week high of $175.91. The company has a quick ratio of 0.75, a current ratio of 0.84 and a debt-to-equity ratio of 4.15. The firm has a 50 day moving average of $141.77 and a 200-day moving average of $149.53.
上週五，ABBV股票開盤報143.06美元。該公司市值為2,529.4億美元，市盈率為20.26倍，市盈率為4.02倍，貝塔係數為0.72。AbbVie Inc.的52周低點為106.44美元，52周高點為175.91美元。該公司的速動比率為0.75，流動比率為0.84，債務權益比為4.15。該公司的50日移動均線切入位在141.77美元，200日移動均線切入位在149.53美元。
AbbVie Announces Dividend
AbbVie宣佈分紅
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 15th. Investors of record on Friday, October 14th will be given a $1.41 dividend. This represents a $5.64 annualized dividend and a yield of 3.94%. The ex-dividend date of this dividend is Thursday, October 13th. AbbVie's payout ratio is currently 79.89%.
該公司最近還宣佈了季度股息，將於11月15日(星期二)支付。10月14日(星期五)登記在冊的投資者將獲得1.41美元的股息。這意味着5.64美元的年化股息和3.94%的收益率。本次股息除息日期為10月13日星期四。AbbVie的派息率目前為79.89%。
Analysts Set New Price Targets
分析師設定新的價格目標
ABBV has been the subject of a number of research reports. UBS Group dropped their price objective on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Atlantic Securities lowered their price target on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Morgan Stanley lowered their price target on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a report on Monday, August 1st. Argus lowered their price target on shares of AbbVie from $165.00 to $155.00 and set a "buy" rating for the company in a report on Wednesday, August 24th. Finally, Barclays lowered their price target on shares of AbbVie to $160.00 in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $159.35.
ABBV已經成為許多研究報告的主題。瑞銀集團在8月1日週一的一份報告中將艾伯維股票的目標價從154.00美元下調至146.00美元，並將該公司的評級定為“中性”。大西洋證券在8月1日週一的一份報告中將AbbVie的股票目標價從178.00美元下調至162.00美元，並將該公司的評級定為“中性”。摩根士丹利在8月1日週一的一份報告中將艾伯維股票的目標價從191.00美元下調至188.00美元，並對該公司設定了“增持”評級。Argus在8月24日週三的一份報告中將AbbVie的股票目標價從165.00美元下調至155.00美元，並對該公司設定了“買入”評級。最後，巴克萊在8月9日週二的一份報告中將艾伯維的目標股價下調至160.00美元。一名投資分析師對該股的評級為賣出，六名分析師給予持有評級，九名分析師給予買入評級，一名分析師給予該公司強烈買入評級。根據MarketBeat.com的數據，該股目前的平均評級為“中等買入”，平均目標價為159.35美元。
About AbbVie
關於AbbVie
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA，用於注射治療自身免疫和腸道Behçet‘s疾病；SKYRIZI用於治療成人中到重度斑塊型牛皮癬；RINVOQ，用於治療成人患者的中到重度活動性類風濕性關節炎；IMBRUVICA，用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤；以及VENCLEXTA，用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 小盤股的裁員是樓市的晴雨表嗎？
- 需要關注的2只半導體類股走勢逆轉
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。